Icecure MedicalICCM -15.10%46 Days Payable is 137.10 as of Mar. 2026, which is 6% below its 10-year median of 145.80. GuruFocus rates ICCM with a GF Score™ of 46/100 and a GF Value™ of $21.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Icecure Medical ranks better than 79.9% on this metric.
The historical rank and industry rank for Icecure Medical's Days Payable or its related term are showing as below:
ICCM'
s Days Payable Range Over the Past 10 Years
Min: 96.22 Med: 145.8 Max: 177.58
Current: 165.11
During the past 13 years, Icecure Medical's highest Days Payable was 177.58. The lowest was 96.22. And the median was 145.80.
ICCM's Days Payable is ranked better than 79.9% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs ICCM: 165.11
Icecure Medical's Days Payable
declined
from Mar. 2025 (196.63) to Mar. 2026 (137.10).
It may suggest that Icecure Medicalaccelerated paying its suppliers.
Icecure Medical Days Payable Related Terms
Icecure Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Icecure Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Icecure Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icecure Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Icecure Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Icecure Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Icecure Medical (ICCM) has a Days Payable of 137.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Icecure Medical and its competitors. This is near median its historical median of 145.80. Over the past decade, Icecure Medical's Days Payable has ranged from 96.22 to 177.58. According to the industry distribution chart, Icecure Medical ranks #160 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 20.1%.
Is Icecure Medical's Days Payable too high?
Icecure Medical's current Days Payable of 137.10 is near median its 10-year median of 145.80. Over the past 10 years, this metric has ranged from a low of 96.22 to a high of 177.58. The Medical Devices & Instruments industry median Days Payable is 68.14. Icecure Medical's value of 137.10 is 101.2% above this industry median. Based on the distribution chart, Icecure Medical ranks #160 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Icecure Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Icecure Medical's Days Payable compare to IRIX and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Icecure Medical ranks #160 out of 796 companies for Days Payable. This places Icecure Medical in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.14. Icecure Medical's value of 137.10 is 101.2% above this benchmark. Historically, Icecure Medical's own Days Payable has ranged from 96.22 to 177.58 over the past decade. While the company's 10-year median is 145.80 vs. the industry median of 68.14, Icecure Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Icecure Medical's current Days Payable of 137.10 is 101.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Icecure Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Icecure Medical's current Days Payable is 137.10, which is near median its own 10-year median of 145.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icecure Medical stock overvalued right now?
Based on GuruFocus' analysis, Icecure Medical (ICCM) is currently considered Possible Value Trap. The stock's GF Value™ is $21.37, compared to a current price of $5.92 — trading 72.3% below its estimated fair value. The current Days Payable is 137.10, which is near median its 10-year median of 145.80 and 101.2% above the Medical Devices & Instruments industry median of 68.14. Icecure Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Icecure Medical (ICCM), the current Days Payable is 137.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icecure Medical (ICCM) Overvalued in 2026?
Based on GuruFocus' analysis, Icecure Medical stock appears to be undervalued.
The current stock price of $5.92 is trading 72.3% below its estimated GF Value™ of $21.37.
GuruFocus considers Icecure Medical to be Possible Value Trap.
Key valuation signals for ICCM:
Days Payable: 137.10 (near median its 10-year median of 145.80)
GF Value™: $21.37 vs. price of $5.92 (72.3% below fair value)
Industry Position: 101.2% above the Medical Devices & Instruments median (#160 of 796)
No single metric tells the full story. See the ICCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
46GF Score
Get the complete analysis for ICCM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCM has been successfully added to your 
